0.25
0.5
0.75
1.25
1.5
1.75
2
Heart Transplantation and MCS in Advanced Heart Failure
Published on Nov 17, 2017841 Views
Pri srčnem popuščanju srce ne more več prečrpavati dovolj velike količine krvi po telesu za presnovne potrebe, zato so organi slabo preskrbljeni s kisikom in hranilnimi snovmi. Neustrezna prekrvitev o
Related categories
Chapter list
Heart Transplantation and MCS in Advanced Heart Failure00:00
CVD deaths vs. cancer deaths by age (US)06:31
Hospital Discharges (in millions)06:54
Heart Failure Facts07:07
Etiologies of heart failure07:52
HF Mortality associated with Continuous Inotropic Infusions08:06
End Stage Heart Failure08:20
Heart failure09:29
Heart Transplantation - 109:48
Christian Barnard10:39
Heart Transplantation - 211:52
Summary of Heart Transplants11:57
Richenbacher, MCS, 199912:30
1976 – Discovery Cyclosporine A13:23
Most Common Transplantation14:07
Immunologic Analysis14:12
Technique - 115:18
Technique - 215:21
Technique - 315:34
Heart Transplantation - 315:47
Adult and Pediatric Heart Transplants - 115:50
Adult and Pediatric Heart Transplants - 216:35
Adult and Pediatric Heart Transplants - 316:41
Adult Heart Transplants - 118:28
Adult Heart Transplants - 218:33
Rejection18:42
Grade 3R, Severe (3B)19:05
Adult Heart Transplants - 319:38
Adult Heart Transplants - 420:16
Adult Heart Transplants - 520:25
Adult Heart Transplants - 620:32
Adult Heart Transplants - 720:45
Adult Heart Transplants - 820:46
Adult Heart Transplants - 920:47
Adult Heart Transplants - 1021:00
Sleh 198721:16
MCS in Chronic Heart Failure21:52
First Clinical LVAD22:06
First Clinical LVAD Success - 122:48
First Clinical LVAD Success - 223:14
Mid 80’s23:22
First generation Pulsatile Devices for Long Term Use - 123:48
First generation Pulsatile Devices for Long Term Use - 224:17
First generation Pulsatile Devices for Long Term Use - 324:46
HeartMate XVE - 125:08
HeartMate XVE - 225:39
HeartMate XVE - 326:05
Working With HM I26:32
First FDA Approved Device for Destination Therapy26:41
Rematch27:01
Evolution of LVAD Technology27:55
Axial flow second generation LVAD’s28:05
New Technology28:09
Axial Flow Pumps28:28
DeBakey/NASA29:06
DeBakey VAD Pump29:16
Implantation of the Jarvik 200029:44
Different Surgical Approaches30:04
Home Discharge Experience30:07
Portret30:24
HeartMate II - 130:56
HMII Anatomical Placement31:18
Original Article31:20
Actuarial Survival vs REMATCH31:23
Patient Quality of Life31:52
HeartMate II - 232:02
HeartMate II - 332:09
Third Generation Blood Pumps33:08
DuraHeart LVAD33:20
The world’s first commercially available Mag-Lev33:22
DuraHeart External Components33:25
DuraHeart Long Term Biocompatibility33:42
HeartWare LVAD34:11
HeartWare LVAS34:36
Evaluation of the HeartWare34:45
ADVANCE Trial Secondary Outcome: Survival34:48
MCS Complications35:22
Perioperative Bleeding35:25
Pericardial Placement with no pocket – a Key Advantage35:41
Blood transfusion35:53
Driveline infection36:19
Infection - 136:24
Infection - 236:38
Importance of Nutrition36:56
TET systems37:05
GI Bleeding37:26
GI bleeding/AVMs37:57
Patients and Methods38:58
AVMs stomach39:03
Pump Thrombosis39:42
LVAD Thrombosis39:49
Non Pump related Thrombosis of LVAD40:13
Dislodgement of outflow cannula40:16
Pump replacement40:20
Disconnected Bend relief graft40:40
HeartMate-II Outflow Graft and Bend Relief40:43
OBR damage to graft during exposure for Heart Transplant40:56
Normal connection41:08
Evolution of LVAD Technology41:11
Pump related Thrombosis of LVAD41:12
Bearings – Potentially heat generated in this area - 141:19
Bearings – Potentially heat generated in this area - 241:45
Blood Damage41:47
Hemolysis41:51
Platelet Trajectories - 142:07
Platelet Trajectories - 242:09
Platelet Trajectories - 342:11
Platelet Trajectories - 442:23
Platelet Trajectories - 542:28
Platelet Trajectories - 642:46
Platelet Trajectories - 742:53
Platelet Trajectories - 843:00
Platelet Trajectories - 943:01
Findings43:04
Clinical studies43:17
H-Vad43:29
Endurance trial - 143:37
Endurance trial - 243:41
Endurance trial - 343:52
Prevent - 144:22
Prevent - 244:26
Algorithm for the Diagnosis and Management of Pump Thrombosis44:35
Prevent - 344:46
Results44:54
Conclusion45:14
New LVAD Trials45:41
HM III45:43
HeartMate III: Design Goals45:57
A Healthy Respect for the Blood46:00
Design Configuration46:17
HeartMate III: Full MagLev Technology46:23
How much difference is there?46:33
HeartMate III: Artificial Pulse46:52
Future47:07
Miniature VAD Development47:18
Future LVADs47:24
Center for Advanced Heart Failure Research Division47:43
Thank You47:59